Lead Product(s) : TrenibotulinumtoxinE
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AGN-151586 (trenibotulinumtoxinE) is a first-in-class, short-acting neurotoxin, which is investigated for the treatment of Glabellar Lines. If approved, BoNT/E will be the first neurotoxin of its kind available to patients.
Product Name : AGN-151586
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 24, 2023
Lead Product(s) : TrenibotulinumtoxinE
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onabotulinumtoxin A
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Botox Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow's feet in adults.
Product Name : Botox
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
September 18, 2023
Lead Product(s) : Onabotulinumtoxin A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosmo Begins Phase III Trials for Androgenetic Alopecia in Males
Details : CB-03-01 (clascoterone) solution is an androgen receptor inhibitor which is currently being evaluated for the treatment of patients with androgenetic alopecia.
Product Name : Winlevi
Product Type : Steroid
Upfront Cash : Inapplicable
June 29, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NAC-GED-0507
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Torii Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan for the treatment of acne vulgaris. NAC-GED-0507 is an IP protected, Phase III-ready, small molecule selective modulator of ...
Product Name : NAC-GED-0507
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 26, 2023
Lead Product(s) : NAC-GED-0507
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Torii Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Benzoyl Peroxide
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Sol-Gel Technologies
Deal Size : Undisclosed
Deal Type : Agreement
Details : Consistent with Sol-Gel’s prior agreements, Perrigo will seek regulatory approval with the U.S. FDA for these generic product candidates. If approved by the FDA, Perrigo will lead the commercialization efforts for the generic product candidates in the ...
Product Name : Epsolay
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 29, 2020
Lead Product(s) : Benzoyl Peroxide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Sol-Gel Technologies
Deal Size : Undisclosed
Deal Type : Agreement